Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

The Resistance Rate of Helicobacter Pylori to Clarithromycin and Main Mutations on Bacterial Genomic Responsible for Bacterial Resistance: A Comparative Study in Children and Adults, Tehran and Iran

Author(s): Azizollah Yousefi, Shahryar Eslami, Samileh Noorbakhsh*, Morteza Haghighi, Leila TaheriNia, Fahimeh Ehsanipour and Sarvenaz Ashouri

Volume 19, Issue 4, 2019

Page: [394 - 397] Pages: 4

DOI: 10.2174/1871526518666181012113052

Price: $65

conference banner
Abstract

Background: High resistance to common antibiotics has become a huge global dilemma in eradicating Helicobacter Pylori infection in both children and adults. The great concern is about the resistance to different classes of antibiotics especially Clarithromycin because of its widespread use.

Objectives: The present survey aimed to assess the resistance rate to Clarithromycin in Helicobacter Pylori isolated in patients aged less than 15 years as compared to patients older than 15 years of age.

Methods: In this cross-sectional study, total 72 patients with upper gastrointestinal symptoms requiring diagnostic endoscopy referred to Rasoul-e-Akram Hospital in Tehran during one year (August 2015 to August 2016). Helicobacter Pylori infection was diagnosed in patients using the Rapid Urease Test. The antibiotics resistance was detected in genomes using the real-time polymerase chain reaction (PCR) on 23S rRNA gene.

Results: In total 72 patients, 36 cases aged less than or equal to 15 years and 36 patients were older than 15 years. Of all patients in this study, 17 cases were detected with gene mutations or polymorphisms related to resistance to Clarithromycin. Overall prevalence rate of resistance was reported 23.61%. Three polymorphisms on 23S rRNA gene including A2142G, A2142C, and A2143G were revealed in 47.1%, 5.9%, and 47.1% of patients, respectively. The bacterial resistance to Clarithromycin was observed more prevalent in patients that aged older than 15 years compared to patients younger than 15 years of age. Also, frequent consumption of any type of antibiotics was significantly associated with the higher resistance of bacterium to Clarithromycin.

Conclusion: The results of our study regarding the resistance of Helicobacter Pylori to Clarithromycin were similar to findings of other studies around the world. But, the Clarithromycin resistance rate was reported higher in patients older than 15 years of age and those patients who repeatedly received different types of antibiotics regardless of their age. Of all mutations in bacterial genome, the prominent mutations responsible for bacterial resistance to Clarithromycin included A2142C, A2142G, and A2143G nucleotide polymorphism on 23S rRNA gene.

Keywords: Helicobacter Pylori, clarithromycin, resistance, gene, gastrointestinal symptoms, asymptomatic.

Graphical Abstract

[1]
Hooi, J.K.Y.; Lai, W.Y.; Ng, W.K.; Suen, M.M.Y.; Underwood, F.E.; Tanyingoh, D.; Malfertheiner, P.; Graham, D.Y.; Wong, V.W.S.; Wu, J.C.Y.; Chan, F.K.L.; Sung, J.J.Y.; Kaplan, G.G.; Ng, S.C. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology, 2017, 153(2), 420-429.
[http://dx.doi.org/10.1053/j.gastro.2017.04.022] [PMID: 28456631]
[2]
Peleteiro, B.; Bastos, A.; Ferro, A.; Lunet, N. Prevalence of Helicobacter pylori infection worldwide: A systematic review of studies with national coverage. Dig. Dis. Sci., 2014, 59(8), 1698-1709.
[http://dx.doi.org/10.1007/s10620-014-3063-0] [PMID: 24563236]
[3]
Bardhan, P.K. Epidemiological features of Helicobacter pylori infection in developing countries. Clin. Infect. Dis., 1997, 25(5), 973-978.
[http://dx.doi.org/10.1086/516067] [PMID: 9402340]
[4]
Salih, B.A. Helicobacter pylori infection in developing countries: The burden for how long? Saudi J. Gastroenterol., 2009, 15(3), 201-207.
[http://dx.doi.org/10.4103/1319-3767.54743] [PMID: 19636185]
[5]
Eusebi, L.H.; Zagari, R.M.; Bazzoli, F. Epidemiology of Helicobacter pylori infection. Helicobacter, 2014, 19(Suppl. 1), 1-5.
[http://dx.doi.org/10.1111/hel.12165] [PMID: 25167938]
[6]
Ishaq, S.; Nunn, L. Helicobacter pylori and gastric cancer: A state of the art review. Gastroenterol. Hepatol. Bed Bench, 2015, 8(Suppl. 1), S6-S14.
[PMID: 26171139]
[7]
Hu, Q.; Zhang, Y.; Zhang, X.; Fu, K. Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori infection: A review of current diagnosis and management. Biomark. Res., 2016, 4, 15.
[http://dx.doi.org/10.1186/s40364-016-0068-1] [PMID: 27468353]
[8]
Sugiyama, T.; Asaka, M. Helicobacter pylori infection and gastric cancer. Med. Electron Microsc., 2004, 37(3), 149-157.
[http://dx.doi.org/10.1007/s00795-004-0250-7] [PMID: 15449106]
[9]
Huang, C.C.; Tsai, K.W.; Tsai, T.J.; Hsu, P.I. Update on the first-line treatment for Helicobacter pylori infection - a continuing challenge from an old enemy. Biomark. Res., 2017, 5, 23.
[http://dx.doi.org/10.1186/s40364-017-0103-x] [PMID: 28702193]
[10]
De Francesco, V.; Bellesia, A.; Ridola, L.; Manta, R.; Zullo, A. First-line therapies for Helicobacter pylori eradication: A critical reappraisal of updated guidelines. Ann. Gastroenterol., 2017, 30(4), 373-379.
[http://dx.doi.org/10.20524/aog.2017.0166] [PMID: 28655973]
[11]
Arslan, N.; Yılmaz, Ö.; Demiray-Gürbüz, E. Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection. World J. Gastroenterol., 2017, 23(16), 2854-2869.
[http://dx.doi.org/10.3748/wjg.v23.i16.2854] [PMID: 28522904]
[12]
Costa, S.; Soares, J.B.; Gonçalves, R. Efficacy and tolerability of culture-guided treatment for Helicobacter pylori infection. Eur. J. Gastroenterol. Hepatol., 2017, 29(11), 1258-1263.
[http://dx.doi.org/10.1097/MEG.0000000000000960] [PMID: 28877088]
[13]
Mascellino, M.T.; Porowska, B.; De Angelis, M.; Oliva, A. Antibiotic susceptibility, heteroresistance, and updated treatment strategies in Helicobacter pylori infection. Drug Des. Devel. Ther., 2017, 11, 2209-2220.
[http://dx.doi.org/10.2147/DDDT.S136240] [PMID: 28814829]
[14]
Gościniak, G.; Biernat, M.M.; Bińkowska, A.; Kus, A.; Iwańczak, B. Frequency of infection with Helicobacter pylori isolates of different antimicrobial profiles in children and adolescents: A preliminary study. Adv. Clin. Exp. Med., 2017, 26(2), 263-268.
[PMID: 28791844]
[15]
Khademi, F.; Sahebkar, A.H.; Vaez, H.; Arzanlou, M.; Peeridogaheh, H. Characterization of clarithromycin-resistant Helicobacter pylori strains in Iran: A systematic review and meta-analysis. J. Glob. Antimicrob. Resist., 2017, 10, 171-178.
[http://dx.doi.org/10.1016/j.jgar.2017.05.021] [PMID: 28732793]
[16]
Mahmoudi, S.; Mamishi, S.; Banar, M.; Keshavarz Valian, S.; Bahador, A.; Najafi, M.; Farahmand, F.; Pourakbari, B. Antibiotic susceptibility of Helicobacter pylori strains isolated from Iranian children: High frequency of A2143G point mutation associated with clarithromycin resistance. J. Glob. Antimicrob. Resist., 2017, 10, 131-135.
[http://dx.doi.org/10.1016/j.jgar.2017.04.011] [PMID: 28720314]
[17]
Monno, R.; Giorgio, F.; Carmine, P.; Soleo, L.; Cinquepalmi, V.; Ierardi, E. Helicobacter pylori clarithromycin resistance detected by Etest and TaqMan real-time polymerase chain reaction: A comparative study. APMIS, 2012, 120(9), 712-717.
[http://dx.doi.org/10.1111/j.1600-0463.2012.02896.x] [PMID: 22882260]
[18]
Beckman, E.; Saracino, I.; Fiorini, G.; Clark, C.; Slepnev, V.; Patel, D.; Gomez, C.; Ponaka, R.; Elagin, V.; Vaira, D. A novel stool PCR test for Helicobacter pylori may predict clarithromycin resistance and eradication of infection at a high rate. J. Clin. Microbiol., 2017, 55(8), 2400-2405.
[http://dx.doi.org/10.1128/JCM.00506-17] [PMID: 28515219]
[19]
Tamayo, E.; Montes, M.; Fernández-Reyes, M.; Lizasoain, J.; Ibarra, B.; Mendarte, U.; Zapata, E.; Mendiola, J.; Pérez-Trallero, E. Clarithromycin resistance in Helicobacter pylori and its molecular determinants in Northern Spain, 2013-2015. J. Glob. Antimicrob. Resist., 2017, 9, 43-46.
[http://dx.doi.org/10.1016/j.jgar.2016.12.019]
[20]
Aguilera-Correa, J.J.; Urruzuno, P.; Barrio, J.; Martinez, M.J.; Agudo, S.; Somodevilla, A.; Llorca, L.; Alarcón, T. Detection of Helicobacter pylori and the genotypes of resistance to clarithromycin and the heterogeneous genotype to this antibiotic in biopsies obtained from symptomatic children. Diagn. Microbiol. Infect. Dis., 2017, 87(2), 150-153.
[http://dx.doi.org/10.1016/j.diagmicrobio.2016.03.001] [PMID: 27863951]
[21]
Quek, C.; Pham, S.T.; Tran, K.T.; Pham, B.T.; Huynh, L.V.; Luu, N.B.; Le, T.K.; Quek, K.; Pham, V.H. Antimicrobial susceptibility and clarithromycin resistance patterns of Helicobacter pylori clinical isolates in Vietnam. F1000 Res., 2016, 13(5), 671.
[http://dx.doi.org/10.12688/f1000research.8239.1]
[22]
Gehlot, V.; Mahant, S.; Mukhopadhyay, A.K.; Das, K.; Alam, J.; Ghosh, P.; Das, R. Low prevalence of clarithromycin-resistant Helicobacter pylori isolates with A2143G point mutation in the 23S rRNA gene in North India. J. Glob. Antimicrob. Resist., 2016, 6, 39-43.
[http://dx.doi.org/10.1016/j.jgar.2016.02.007] [PMID: 27530837]

Rights & Permissions Print Cite
Article Metrics
19
1
© 2024 Bentham Science Publishers | Privacy Policy